SCHEMBL17824670

SCHEMBL17824670

Cc1ccc(C)n1-c1ncc(CO)s1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OGA O60502 1/20 0.39
HRH3 Q9Y5N1 1/20 0.36
KDM4E B2RXH2 4/20 0.35
SRC P12931 1/20 0.35
ZAP70 P43403 1/20 0.35
SYK P43405 1/20 0.35
ALDH1A1 P00352 7/20 0.33
MAPT P10636 4/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
GAA P10253 2/20 0.33
HTT P42858 2/20 0.33
TSHR P16473 1/20 0.33
POLB P06746 2/20 0.32
CCR6 P51684 1/20 0.32
MAPK1 P28482 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
LMNA P02545 1/20 0.30
HPGD P15428 1/20 0.30
RECQL P46063 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22175730 0.82 KDM4E (0.35) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL6799679 0.75 NOS1 (0.41) OGAKDM4EALDH1A1MAPTMEN1
SCHEMBL1871602 0.73 KDM4E (0.48) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL22175659 0.71 ALDH1A1 (0.41) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL10312551 0.71 TDO2 (0.38) OGAHRH3KDM4ESRCZAP70
SCHEMBL12469946 0.70 OGA (0.38) OGAHRH3ALDH1A1MAPTMEN1
SCHEMBL1107383 0.70
SCHEMBL22175658 0.68 CDC7 (0.55) OGAKDM4EALDH1A1MAPTMEN1
SCHEMBL10187132 0.66 HCAR2 (0.49) OGAHRH3ALDH1A1MEN1KMT2A
SCHEMBL30963488 0.65 GPX4 (0.37) MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10239843-B2 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-03-26 US disclosed
US-20180016242-A1 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-01-18 US disclosed
EP-3230273-A1 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG Cancer Research Technology Ltd (GB) 2017-10-18 EP disclosed
WO-2016092326-A1 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180016242-A1 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG PARG, PARP15, PARP12 OGA 1476/4885HRH3 493/4885KDM4E 837/4885
US-10239843-B2 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG PARG, PARP15, PARP12 OGA 1476/4885HRH3 493/4885KDM4E 837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.